Moleculin Biotech Inc MBRX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if MBRX is a good fit for your portfolio.
News
-
Moleculin Biotech (NASDAQ:MBRX) Participates in Virtual Investor "What This Means" Segment Hosted by JTC Team
-
European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML)
-
Moleculin Announces Presentation of Positive Data Demonstrating High Anti-Cancer Activity of Annamycin and Non-Cardiotoxic Properties
-
Moleculin to Present at the MedInvest Biotech & Pharma Investor Conference
-
Moleculin to Participate in the Virtual Investor Lunch Break: The Moleculin Opportunity
-
Moleculin Announces U.S. Patent Issue Notification for Annamycin Targeting Unmet Need in AML
-
Moleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial
-
Moleculin Reports Full Year 2023 Financial Results
Trading Information
- Previous Close Price
- $4.31
- Day Range
- $4.41–4.90
- 52-Week Range
- $4.28–15.75
- Bid/Ask
- $4.41 / $4.79
- Market Cap
- $10.31 Mil
- Volume/Avg
- 23,988 / 35,738
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of highly resistant tumors and viruses. The company’s lead program, Annamycin is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 18
- Website
- https://www.moleculin.com
Valuation
Metric
|
MBRX
|
---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.37 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric
|
MBRX
|
---|---|
Quick Ratio | 3.47 |
Current Ratio | 3.86 |
Interest Coverage | — |
Quick Ratio
MBRX
Profitability
Metric
|
MBRX
|
---|---|
Return on Assets (Normalized) | −57.30% |
Return on Equity (Normalized) | −67.07% |
Return on Invested Capital (Normalized) | −69.76% |
Return on Assets
MBRX
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Gcgprqbwvz | Bxlqw | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Gbbjgldzs | Fzpgvrk | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Ywzwzlwhc | Cxwtm | $97.8 Bil | |
MRNA
| Moderna Inc | Wpzgshtbh | Zzdzx | $38.8 Bil | |
ARGX
| argenx SE ADR | Czykzch | Ktzm | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Gwlmqfmj | Ppykh | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Smsrqjvv | Lytrsqm | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Grdscgpp | Cfxfd | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Vghrmrmtwk | Ncxbvdz | $12.5 Bil | |
INCY
| Incyte Corp | Lckjvygj | Bfzdy | $11.5 Bil |